Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Laura Gault, MD
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 84173
Gatineau, Canada
- Site Reference Id/investigator# 84174
Montreal, Canada
- Site Reference Id/investigator# 84177
Peterborough, Canada
- Site Reference Id/investigator# 84175
Toronto, Canada
- Site Reference Id/investigator# 84176
Verdun, Canada
- Site Reference Id/investigator# 84376
Dijon, France
- Site Reference Id/investigator# 84373
Limoges, France
- Site Reference Id/investigator# 84374
Paris, France
- Site Reference Id/investigator# 84377
Paris, France
- Site Reference Id/investigator# 84375
Toulouse, France
- Site Reference Id/investigator# 84382
Berlin, Germany
- Site Reference Id/investigator# 84380
Freiburg im Breisgau, Germany
- Site Reference Id/investigator# 84383
Hüttenberg, Germany
- Site Reference Id/investigator# 84379
Mittweida, Germany
- Site Reference Id/investigator# 84381
Munich, Germany
- Site Reference Id/investigator# 84378
Schwerin, Germany
- Site Reference Id/investigator# 84385
Athens, Greece
- Site Reference Id/investigator# 84388
Athens, Greece
- Site Reference Id/investigator# 84389
Athens, Greece
- Site Reference Id/investigator# 84386
Haidari, Athens, Greece
- Site Reference Id/investigator# 84390
Thessaloniki, Greece
- Site Reference Id/investigator# 84395
Belville, South Africa
- Site Reference Id/investigator# 84391
Cape Town, South Africa
- Site Reference Id/investigator# 84393
George, South Africa
- Site Reference Id/investigator# 84394
Johannesburg, South Africa
- Site Reference Id/investigator# 84392
Rosebank, South Africa
- Site Reference Id/investigator# 84398
Bath, United Kingdom
- Site Reference Id/investigator# 84397
Glasgow, United Kingdom
- Site Reference Id/investigator# 84400
London, United Kingdom
- Site Reference Id/investigator# 84399
Manchester, United Kingdom
- Site Reference Id/investigator# 84185
Long Beach, California, United States
- Site Reference Id/investigator# 84183
San Francisco, California, United States
- Site Reference Id/investigator# 84187
Hamden, Connecticut, United States
- Site Reference Id/investigator# 84178
Delray Beach, Florida, United States
- Site Reference Id/investigator# 84180
Orlando, Florida, United States
- Site Reference Id/investigator# 84186
West Palm Beach, Florida, United States
- Site Reference Id/investigator# 84182
Elk Grove Village, Illinois, United States
- Site Reference Id/investigator# 84181
Staten Island, New York, United States
- Site Reference Id/investigator# 84179
Bennington, Vermont, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2012
- Primary completion
- 28 Feb 2014
- Completion
- 28 Feb 2014
- Last update posted
- 2 Aug 2021
- Registered enrollment
- 343
- Registry id
- NCT01690195
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.